Table 2.

Statistically significant SNPs replicated in the PGSNPS dataset (phenotype: TRSN cumulative dose analysis)

GeneVariantSNP rs number and nucleotide changeChromosomePosition DBSNP build 37Major/minor alleleType of SNP genotyped (G) imputed (I)Imputation R2HRa95% CIaP-valueIncluded in AML yes (Y) no (N)
CYP2C8*4rs10589301096818119G/CG1.381.03–1.860·04Y
ABCB1rs2032582787160618C/AI0.991.191.04–1.380·02Y
ABCB1**rs1045642787138645A/GG0.830.72–0.950·009N [high correlation with other SNP(s)]
ABCB1rs3213619787230193A/GI0.990.510.31–0.850·004Y
ABCC2rs818771010101611294G/AI10.710.50–1.020·05Y
CYP1B1*3rs1056836238298203G/CG0.830.72–0.960·01Y
TUBB2Ars950192963157854T/CI0.961.601.18–2.180·005Y
SLCO1B1brs38293061221292280C/TI0.990.670.46–0.970.02Y
C19orf21rs811053619756985T/GI0.371.371.01–1.870.05Y
EPHA6rs301927397346618A/GI0.991.291.07–1.550.008Y

Not all variants described in each study as having “no association with neuropathy” are reported in the table.

OR > 1 indicates an increased risk of TRSN.

OR < 1 indicates a decreased risk of TRSN.

  • aHRs and 95% CIs represent the per-allele effect of the minor allele for any particular SNP.

  • brs3829306 is in complete LD with rs4149013 and rs4149023, both in SLCO1B1.